Drug Profile


Latest Information Update: 29 Dec 1999

Price : $50

At a glance

  • Originator Provalis
  • Developer International Diabetes Institute
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 29 Dec 1999 Discontinued-II for Diabetic neuropathies in Australia (Topical)
  • 03 Dec 1999 Cortecs is now called Provalis
  • 15 Oct 1999 Profile reviewed, but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top